INMB
INmune Bio, Inc.
There isn't enough reported data to score INMB yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
INMB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INMB's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INMB PE Valuation
INMB has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INMB's revenue to decline, with its earnings and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
INMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$1.56 |
| Q2 2026 | -$0.63 | +$1.85 |
| Q1 2026 | -$1.63 | +$0.30 |
| Q4 2025 | -$1.86 | +$0.25 |
| Q3 2025 | -$2.12 | +$0.06 |
| Q2 2025 | -$2.48 | -$0.42 |
| Q1 2025 | -$1.93 | -$0.01 |
| Q4 2024 | -$2.11 | -$0.44 |
INMB is still losing money, but far less than before: $0.56 per share over the past year, against $2.48 at its worst in mid-2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over INMB on earnings quality, reporting a profit while its opponent remains loss making.
INMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $50K | +257% |
| Q1 2024 | $14K | -63% |
| Q4 2023 | $28K | -71% |
| Q3 2023 | $43K | -56% |
| Q2 2023 | $46K | +188% |
| Q1 2023 | $38K | -77% |
| Q4 2022 | $97K | -40% |
| Q3 2022 | $98K | +600% |
INMB's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -19810% | +58883 points |
| Q1 2024 | -78693% | -61790 points |
| Q4 2023 | -29925% | -24109 points |
| Q3 2023 | -19833% | -12238 points |
| Q2 2023 | -13937% | +25988 points |
| Q1 2023 | -16903% | -12928 points |
| Q4 2022 | -5816% | -277 points |
| Q3 2022 | -7595% | +56841 points |
INMB's operating margin was −19810% last quarter, down 5873 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
INMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | +$2.2M |
| Q1 2026 | -$3.4M | +$3.4M |
| Q4 2025 | -$3.1M | +$7.9M |
| Q3 2025 | -$5.6M | +$1.4M |
| Q1 2025 | -$6.8M | +$652K |
| Q4 2024 | -$11M | -$7.6M |
| Q3 2024 | -$7M | -$2.7M |
| Q2 2024 | -$7.9M | -$4.7M |
INMB has burned cash in almost every quarter: −$13M over the past year, against −$30M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over INMB on cash generation, producing positive trailing cash flow while its opponent burns cash.
INMB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +1.1M shares |
| 1 year | +4.6% | +1.2M shares |
| 3 years | +54% | +9.8M shares |
| 5 years | +60% | +10.5M shares |
| Available history | +171% | +17.5M shares |
INMB has 28M diluted shares, up 4.6% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over INMB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INMB Net Leverage
INMB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 3.7 | Oversold |
INMB's weekly RSI is 32 (neutral) and its Stochastic is 4 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INMB PE vs Healthcare Sector
INMB has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.56 | 33% below |
| 20 week MA | $1.87 | 44% below |
| 50 week MA | $1.63 | 36% below |
| 100 week MA | $3.33 | 68% below |
| 200 week MA | $5.90 | 82% below |
INMB is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over INMB on trend strength, trading above more of its moving averages.
INMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.35 | $12.8 | +138% |
| 2021 | $12.8 | $10.9 | -15% |
| 2022 | $10.9 | $7.03 | -35% |
| 2023 | $7.03 | $11.3 | +60% |
| 2024 | $11.3 | $4.65 | -59% |
| 2025 | $4.65 | $1.73 | -63% |
| 2026 YTD | $1.73 | $1.05 | -39% |
INMB's yearly returns have swung widely, from +138% in 2020 to −63% in 2025. It's down 39% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over INMB on returns for 2026, with the stronger performance.